Nyxoah posted €1.34 million in revenue for Q2 2025, a 74% increase YoY, following the FDA approval of its Genio system and the beginning of its U.S. commercial launch. The company reported a net loss of €20.6 million, driven by increased commercialization and R&D investments.

Nyxoah recorded €1.1 million in revenue for Q1 2025, slightly below last year. The company's operating loss widened to €20.6 million as it ramped up expenses in preparation for the U.S. commercialization of its Genio® system. With the FDA approval process nearing completion, Nyxoah maintained a strong cash position to support its strategic objectives.

Nyxoah's Q4 2024 revenue reached €1.3 million, with a gross margin of 73%. However, increased research and development expenses contributed to a higher operating loss of €18.3 million. The company is preparing for its U.S. commercial launch in March 2025, following anticipated FDA approval.